Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

NCT01910480 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

Interventions

DRUG: NBI-98854 50 mg capsule once daily
DRUG: Ketoconazole 400 mg (200 mg twice daily)

Sponsor

Neurocrine Biosciences